See more : Atlanta Limited (ATLANTA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of TCR2 Therapeutics Inc. (TCRR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TCR2 Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Terex Corporation (TEX) Income Statement Analysis – Financial Results
- Tanfac Industries Limited (TANFACIND.BO) Income Statement Analysis – Financial Results
- TSI Holdings Co.,Ltd. (TSIHF) Income Statement Analysis – Financial Results
- Second Sight Medical Products, Inc. (EYES) Income Statement Analysis – Financial Results
- Hi-Target Navigation Tech Co.,Ltd (300177.SZ) Income Statement Analysis – Financial Results
TCR2 Therapeutics Inc. (TCRR)
About TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.64M | 77.24M | 51.98M | 37.49M | 19.67M | 9.57M | 7.67M |
| General & Administrative | 24.44M | 22.50M | 16.72M | 13.89M | 6.78M | 3.61M | 2.26M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.44M | 22.50M | 16.72M | 13.89M | 6.78M | 3.61M | 2.26M |
| Other Expenses | 30.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 123.08M | 99.74M | 68.70M | 51.38M | 26.45M | 13.18M | 9.93M |
| Cost & Expenses | 123.08M | 99.74M | 68.70M | 51.38M | 26.45M | 13.18M | 9.93M |
| Interest Income | 1.94M | 224.00K | 1.74M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 63.88M | 2.83M | 1.59M | 862.00K | 419.00K | 298.00K | 220.00K |
| EBITDA | -89.62M | -96.92M | -67.11M | -50.52M | -23.83M | -12.77M | -9.70M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -153.50M | -99.74M | -68.70M | -51.38M | -26.45M | -13.18M | -9.93M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.94M | 224.00K | 1.74M | 3.89M | 2.20M | 110.00K | 15.00K |
| Income Before Tax | -151.56M | -99.52M | -66.96M | -47.50M | -24.25M | -13.07M | -9.92M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 261.00K | 289.00K | 161.00K | 102.00K | 2.20M | 110.00K | 15.00K |
| Net Income | -151.82M | -99.81M | -67.12M | -47.60M | -24.25M | -13.07M | -9.92M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.93 | -2.63 | -2.40 | -2.26 | -1.05 | -2.55 | -1.93 |
| EPS Diluted | -3.93 | -2.63 | -2.40 | -2.26 | -1.05 | -2.55 | -1.93 |
| Weighted Avg Shares Out | 38.63M | 37.94M | 27.99M | 21.10M | 23.19M | 5.13M | 5.13M |
| Weighted Avg Shares Out (Dil) | 38.63M | 37.94M | 27.99M | 21.10M | 23.19M | 5.13M | 5.13M |
5 Penny Stocks To Buy According To Analysts, Targets Up To 952%
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
TCR² Therapeutics: Betting On A Solid Reversal
TCR² Therapeutics to Participate in Two Upcoming Conferences in June
Source: https://incomestatements.info
Category: Stock Reports